Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Revolution Medicines (RVMD) Non Operating Income (2019 - 2025)

Revolution Medicines (RVMD) has 7 years of Non Operating Income data on record, last reported at -$3.3 million in Q4 2025.

  • For Q4 2025, Non Operating Income fell 103.58% year-over-year to -$3.3 million; the TTM value through Dec 2025 reached $51.1 million, down 52.64%, while the annual FY2025 figure was $51.1 million, 42.41% down from the prior year.
  • Non Operating Income reached -$3.3 million in Q4 2025 per RVMD's latest filing, down from $10.1 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $91.2 million in Q4 2024 and bottomed at -$27.6 million in Q2 2024.
  • Average Non Operating Income over 5 years is $10.8 million, with a median of $4.0 million recorded in 2022.
  • The widest YoY moves for Non Operating Income: up 2237.42% in 2023, down 914.19% in 2023.
  • A 5-year view of Non Operating Income shows it stood at $237000.0 in 2021, then surged by 2042.19% to $5.1 million in 2022, then skyrocketed by 615.91% to $36.3 million in 2023, then surged by 150.88% to $91.2 million in 2024, then tumbled by 103.58% to -$3.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non Operating Income were -$3.3 million in Q4 2025, $10.1 million in Q3 2025, and $16.9 million in Q2 2025.